Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 23

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 23
---
 and AD. The second award of $498,572 was granted to DiamiR by the National Institute for Neurological Disorders and Stroke (NINDS) for a project entitled “Circulating Organ-enriched microRNAs as biomarkers of Rett Syndrome.” From June 2020 through April 2023, Kira Sheinerman, one of the founders and the Executive Director of DiamiR, served as senior strategic consultant to Aptorum, which role included reviewing therapeutic and diagnostic opportunities, and making industry and academia introductions for Aptorum. Kira Sheinerman currently hold 2,772 shares of Aptorum. Company management believes that by merging these two companies together, it can achieve greater shareholder value and have a stronger growth trajectory. Merger Agreement with DiamiR Pursuant to the Letter of Intent, we entered into the Merger Agreement with DiamiR on July 14, 2025 for the DiamiR Merger. Pursuant to the Merger Agreement, the Company will newly incorporate a wholly owned, direct subsidiary in the state of Delaware for purposes of consummating the transactions contemplated therein (the “Merger Sub”). At the closing, subject to terms and conditions of the Merger Agreement, the Merger Sub will merge with and into DiamiR, with DiamiR surviving, resulting in DiamiR becoming a direct wholly-owned subsidiary of the Company. Prior to the closing of DiamiR Merger, the Company will transfer by way of continuation to and domesticate as a Delaware corporation (the “Domestication”; the Company immediately following the Domestication and prior to the closing of DiamiR Merger, “Aptorum Delaware”). In connection with the Domestication, each then issued and outstanding Class A ordinary share of the Company will convert automatically, on a one-for-one basis, into a share of common stock of Aptorum Delaware, each then issued and outstanding Class B ordinary share of the Company will convert automatically, on a one-for-one basis, into a share of common stock of Aptorum Delaware and a share of non-voting and non-convertible Series A preferred stock of Aptorum Delaware. 6 At the closing of DiamiR Merger, in exchange for all the outstanding common stock of DiamiR, Aptorum Delaware will issue shares of its common stock to stockholders of DiamiR (excluding the dissenting stockholders to DiamiR Merger), at a pre-determined conversion ratio to the extent that the stockholders of D